| HOME >> BIOLOGY >> TECHNOLOGY |
(EPZICOM)
FIRAZYR(R) (icatibant) (trademark of Jerini)
FOSRENOL(R) (lanthanum carbonate)
INTUNIV(TM) (guanfacine - extended release)
JUVISTA(R) (human TGFIsquared3) (trademark of Renovo)
LIALDA(R) (mesalamine)
METAZYM(TM) (arylsulfatase-A)
MEZAVANT(R) (mesalazine)
PENTASA(R) (mesalamine) (trademark of Ferring)
PLICERA(TM) (isofagomine tartrate) (trademark of Amicus)
RAZADYNE(R) (galantamine) (trademark of Johnson & Johnson
("J&J"))
RAZADYNE(R) ER (galantamine) (trademark of J&J)
REMINYL(R) (galantamine hydrobromide) (UK and Republic of
Ireland)
REMINYL (galantamine) (trademark of J&J, excluding UK
and Republic of Ireland)
REMINYL XL(TM) (galantamine hydrobromide) (UK and Republic of
Ireland)
REMINYL XL (galantamine) (trademark of J&J, excluding UK
and Republic of Ireland)
REPLAGAL(R) (agalsidase alfa)
VYVANSE(TM) (lisdexamfetamine dimesylate)
XAGRID(TM) (anagrelide hydrochloride)
ZEFFIX (lamivudine) (trademark of GSK)
3TC (lamivudine) (trademark of GSK)
OVERVIEW OF US GAAP FINANCIAL RESULTS
1. Introduction
Summary of Q2 2008 Revenues from operations for the three months to June 30, 2008 increased by 35% to $775.6 million (2007: $574.9 million).
The operating loss for the three months to June 30, 2008 was $67.3
million (2007 loss: $1,775.1 million). The loss in the second quarter of
2008 was due to the $1
'/>"/>
| SOURCE Shire Ltd Copyright©2008 PR Newswire. All rights reserved |